BUZZ-遗传性疾病药物未能达到中期研究的关键次要目标，Disc Medicine 公司股价下跌

Reuters04-01

((自动化翻译由路透提供，请见免责声明 ))

4月1日 - ** 药物开发商Disc Medicine 股价盘前下跌59.8%至25美元

** Co sa (link) ys其治疗一种罕见遗传疾病的试验性药物没有达到中期研究的次要目标

** 该公司称，由于安慰剂的强势表现，药物比托哌汀在改善对日光的耐受性方面没有达到统计学意义。

** 该公司正在测试治疗红细胞生成性原卟啉症的药物，这种疾病会在患者暴露于阳光下时引起严重反应，表现为剧烈疼痛和灼烧感

** 截至收盘股价年累计上涨 7.8

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2424714085?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-01 21:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2424714085","market":"us","top_or_hot":-1,"title":"BUZZ-遗传性疾病药物未能达到中期研究的关键次要目标，Disc Medicine 公司股价下跌","media":"Reuters","content":"<html><body><p>((自动化翻译由路透提供，请见免责声明 ))</p><p>    4月1日 - ** 药物开发商<a href=\"https://laohu8.com/S/IRON\">Disc Medicine</a>   股价盘前下跌59.8%至25美元 </p><p>** Co sa (link) ys其治疗一种罕见遗传疾病的试验性药物没有达到中期研究的次要目标 </p><p>** 该公司称，由于安慰剂的强势表现，药物比托哌汀在改善对日光的耐受性方面没有达到统计学意义。 </p><p>** 该公司正在测试治疗红细胞生成性原卟啉症的药物，这种疾病会在患者暴露于阳光下时引起严重反应，表现为剧烈疼痛和灼烧感 </p><p>** 截至收盘股价年累计上涨 7.8  </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-遗传性疾病药物未能达到中期研究的关键次要目标，Disc Medicine 公司股价下跌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-遗传性疾病药物未能达到中期研究的关键次要目标，Disc Medicine 公司股价下跌\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-01 21:17 北京时间&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>((自动化翻译由路透提供，请见免责声明 ))    4月1日 - ** 药物开发商Disc Medicine   股价盘前下跌59.8%至25美元 ** Co sa (link) ys其治疗一种罕见遗传疾病的试验性药物没有达到中期研究的次要目标 ** 该公司称，由于安慰剂的强势表现，药物比托哌汀在改善对日光的耐受性方面没有达到统计学意义。 ** 该公司正在测试治疗红细胞生成性原卟啉症的药物，这种...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2424714085","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2424714085","pubTimestamp":1711977426,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"((自动化翻译由路透提供，请见免责声明 ))    4月1日 - ** 药物开发商Disc Medicine   股价盘前下跌59.8%至25美元 ** Co sa (link) ys其治疗一种罕见遗传疾病的试验性药物没有达到中期研究的次要目标 ** 该公司称，由于安慰剂的强势表现，药物比托哌汀在改善对日光的耐受性方面没有达到统计学意义。 ** 该公司正在测试治疗红细胞生成性原卟啉症的药物，这种疾病会在患者暴露于阳光下时引起严重反应，表现为剧烈疼痛和灼烧感 ** 截至收盘股价年累计上涨 7.8","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","IRON":"Disc Medicine","BUZZ":"VanEck Social Sentiment ETF"},"translate_title":"BUZZ-hereditary disease drugs failed to meet key secondary goals of mid-term research, and Disc Medicine shares fell","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BUZZ":1,"IRON":1},"content_text":"((自动化翻译由路透提供，请见免责声明 ))    4月1日 - ** 药物开发商Disc Medicine   股价盘前下跌59.8%至25美元 ** Co sa (link) ys其治疗一种罕见遗传疾病的试验性药物没有达到中期研究的次要目标 ** 该公司称，由于安慰剂的强势表现，药物比托哌汀在改善对日光的耐受性方面没有达到统计学意义。 ** 该公司正在测试治疗红细胞生成性原卟啉症的药物，这种疾病会在患者暴露于阳光下时引起严重反应，表现为剧烈疼痛和灼烧感 ** 截至收盘股价年累计上涨 7.8","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2424714085"}